BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34686682)

  • 21. Calcineurin promotes hypoxia-inducible factor 1alpha expression by dephosphorylating RACK1 and blocking RACK1 dimerization.
    Liu YV; Hubbi ME; Pan F; McDonald KR; Mansharamani M; Cole RN; Liu JO; Semenza GL
    J Biol Chem; 2007 Dec; 282(51):37064-73. PubMed ID: 17965024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of Smurf2 as a HIF-1α degrading E3 ubiquitin ligase.
    Zhao S; El-Deiry WS
    Oncotarget; 2021 Sep; 12(20):1970-1979. PubMed ID: 34611473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy.
    Barliya T; Mandel M; Livnat T; Weinberger D; Lavie G
    PLoS One; 2011; 6(9):e22849. PubMed ID: 21949677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia.
    Cheng J; Kang X; Zhang S; Yeh ET
    Cell; 2007 Nov; 131(3):584-95. PubMed ID: 17981124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The involvement of hypoxia-inducible factor 1α (HIF1α)-stabilising factors in steroidogenic acute regulatory (STAR) protein-dependent steroidogenesis in murine KK1 granulosa cells in vitro.
    Gysin T; Kowalewski MP
    Reprod Fertil Dev; 2021 Dec; 33(18):865-880. PubMed ID: 34871543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner.
    Joshi S; Singh AR; Durden DL
    J Biol Chem; 2014 Aug; 289(33):22785-22797. PubMed ID: 24982421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation promotes malignant progression of glioma cells through HIF-1alpha stabilization.
    Kim YH; Yoo KC; Cui YH; Uddin N; Lim EJ; Kim MJ; Nam SY; Kim IG; Suh Y; Lee SJ
    Cancer Lett; 2014 Nov; 354(1):132-41. PubMed ID: 25109450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
    Zhang J; Zhou L; Zhao S; Dicker DT; El-Deiry WS
    Cell Cycle; 2017 Jun; 16(12):1193-1200. PubMed ID: 28486050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
    Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
    Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychologic Stress Drives Progression of Malignant Tumors via DRD2/HIF1α Signaling.
    Liu H; Yang J; Zhang Y; Han J; Yang Y; Zhao Z; Dai X; Wang H; Ding X; Liu Y; Zhong W; Gao W; Sun T
    Cancer Res; 2021 Oct; 81(20):5353-5365. PubMed ID: 34321238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner.
    Flügel D; Görlach A; Michiels C; Kietzmann T
    Mol Cell Biol; 2007 May; 27(9):3253-65. PubMed ID: 17325032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization.
    Liu YV; Semenza GL
    Cell Cycle; 2007 Mar; 6(6):656-9. PubMed ID: 17361105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Down-regulation of HIF-1alpha by oncolytic reovirus infection independently of VHL and p53.
    Cho IR; Koh SS; Min HJ; Park EH; Ratakorn S; Jhun BH; Jeong SH; Yoo YH; Youn HD; Johnston RN; Chung YH
    Cancer Gene Ther; 2010 May; 17(5):365-72. PubMed ID: 20075985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cks1 proteasomal degradation is induced by inhibiting Hsp90-mediated chaperoning in cancer cells.
    Khattar V; Fried J; Xu B; Thottassery JV
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):411-20. PubMed ID: 25544127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
    Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
    Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.
    Lang SA; Moser C; Gaumann A; Klein D; Glockzin G; Popp FC; Dahlke MH; Piso P; Schlitt HJ; Geissler EK; Stoeltzing O
    Clin Cancer Res; 2007 Nov; 13(21):6459-68. PubMed ID: 17975158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1α destabilization by SH-1242 and SH-1280, novel hsp90 inhibitors.
    Jo DH; An H; Chang DJ; Baek YY; Cho CS; Jun HO; Park SJ; Kim JH; Lee HY; Kim KW; Lee J; Park HJ; Kim YM; Suh YG; Kim JH
    J Mol Med (Berl); 2014 Oct; 92(10):1083-92. PubMed ID: 24875598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GRIM-19 opposes reprogramming of glioblastoma cell metabolism via HIF1α destabilization.
    Liu Q; Wang L; Wang Z; Yang Y; Tian J; Liu G; Guan D; Cao X; Zhang Y; Hao A
    Carcinogenesis; 2013 Aug; 34(8):1728-36. PubMed ID: 23580587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
    Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
    Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.